[Strategy for patients with low-risk coronary artery disease: initial medical therapy only or PCI plus medical therapy].
We conducted a randomized trial in which the long-term prognoses obtained with PCI+ medical therapy (P) and Medical therapy only (M) were compared in patients with stable low-risk CAD (JSAP Study). The cumulative risk of death+ACS was significantly smaller in the P group. The incidence of ACS stemming from the PCI-target lesion was significantly lower in the P group. A considerable number of ACS cases may originate from coronary sites with already severe stenosis makes it reasonable to expect that PCI therapy would protect against a future ACS attack by stabilizing the PCI-target lesion as well as reducing stenosis. Therefore, P may improve long-term prognosis more effectively than M, which is different from the result of COURAGE Trial.